Similarly, while very limited in vivo data has been shown, a monoamine oxidase inhibitor, tranylcypromine (TCP) alone or in combination with ATRA has been used to suppress LSD1 activity in MLL48 or non-MLL leukaemia in vitro50 (Table 1), respectively. The gene discussed is KMT2A; the disease is leukemia.